Steve Pakola Sells 19,608 Shares of REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 19,608 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $11.04, for a total value of $216,472.32. Following the sale, the insider directly owned 213,009 shares of the company’s stock, valued at approximately $2,351,619.36. This represents a 8.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steve Pakola also recently made the following trade(s):

• On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The shares were sold at an average price of $11.02, for a total transaction of $168,705.18.

REGENXBIO Stock Performance

NASDAQ RGNX opened at $13.28 on Friday. REGENXBIO Inc. has a 52-week low of $5.45 and a 52-week high of $16.19. The company has a 50-day simple moving average of $8.21 and a 200 day simple moving average of $9.91. The company has a market capitalization of $686.58 million, a PE ratio of -2.37 and a beta of 0.90.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.36). REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The company had revenue of $6.39 million during the quarter, compared to the consensus estimate of $25.84 million. As a group, analysts forecast that REGENXBIO Inc. will post -3.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGNX has been the subject of several research reports. Robert W. Baird increased their price objective on REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, June 22nd. Barclays dropped their price target on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, May 15th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of REGENXBIO in a report on Wednesday. Bank of America lowered their price objective on REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Leerink Partners increased their target price on shares of REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.82.

Institutional Investors Weigh In On REGENXBIO

Several hedge funds and other institutional investors have recently modified their holdings of RGNX. Versant Capital Management Inc boosted its position in shares of REGENXBIO by 60.4% in the second quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 1,032 shares during the period. Aquatic Capital Management LLC purchased a new stake in REGENXBIO in the 3rd quarter worth approximately $37,000. Captrust Financial Advisors purchased a new stake in REGENXBIO in the 2nd quarter worth approximately $85,000. Entropy Technologies LP bought a new position in REGENXBIO in the 1st quarter valued at $87,000. Finally, Prudential Financial Inc. bought a new position in REGENXBIO in the 2nd quarter valued at $87,000. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.